Evaluating Nipocalimab Versus Placebo to Reduce Risk of Fetal and Neonatal Alloimmune Thrombocytopenia in At-Risk Pregnant Women
Led by Janssen Research & Development, LLC · Updated on 2026-11-03
39
Participants Needed
21
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness of nipocalimab compared with placebo to reduce the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT in pregnant women who have had previous pregnancies affected by this condition. This phase 3 study focuses on at-risk pregnancies where the fetus is confirmed to have a specific platelet antigen, and the mother has antibodies against it. The goal is to assess whether nipocalimab can lower the risk of severe bleeding, low platelet counts, or death in the fetus or newborn.
Participants will be randomly assigned to receive either nipocalimab or a placebo intravenously during pregnancy, between weeks 13 and 18 of gestation. The study is double-blind, so neither participants nor researchers know which treatment is given. Maternal health and fetal status will be closely monitored throughout pregnancy and up to 24 weeks postpartum. The study also tracks adverse events, antibody responses, and infant development up to 104 weeks after birth.
Participants will undergo assessments including physical exams, medical history reviews, vital signs, ECGs, and laboratory tests at screening and during the study. Researchers will measure outcomes such as the occurrence of severe bleeding, platelet counts at birth, need for platelet transfusions, and infant development using the Bayley Scales at 52 and 104 weeks. Safety is monitored for both mothers and infants throughout the study period, which lasts until approximately two years after birth.
CONDITIONS
Brief Title
A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Pregnant women between 13 and 18 weeks gestation at randomization
History of at least one prior pregnancy with fetal and neonatal alloimmune thrombocytopenia (FNAIT) with neonatal platelet count less than 150 x 10^9/L
Current pregnancy with maternal anti-human platelet antigen (HPA)-1a antibodies and fetus positive for HPA-1a genotype confirmed by cell-free fetal DNA in maternal blood
Stable health status based on physical exam, medical history, vital signs, ECG, and lab tests at screening
Willingness for both mother and infant to avoid participation in other investigational therapy studies until last follow-up visit
You will not qualify if you...
Currently pregnant with multiple gestations (twins or more)
History of severe preeclampsia in a previous pregnancy
History of myocardial infarction, unstable ischemic heart disease, or stroke
Known allergies or intolerance to nipocalimab or its ingredients
Confirmed or suspected clinical immunodeficiency syndrome or family history of congenital or hereditary immunodeficiency unless confirmed absent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - From randomization until delivery
Participants receive nipocalimab or placebo intravenously during pregnancy between weeks 13 and 18 of gestation.
Regular visits during pregnancy
Postpartum Follow-up
Duration - Up to 2 years after birth
Mothers and infants are monitored for safety and development up to 104 weeks after birth.
Scheduled visits for assessments and monitoring
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Evaluating Nipocalimab Versus Placebo to Reduce Risk of Fetal and Neonatal Alloimmune Thrombocytopenia in At-Risk Pregnant Women
Randomized Study Comparing Nipocalimab and Intravenous Immunoglobulin in Pregnancies at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Plain Language Summary of Publication: Design of the Phase 3 FREESIA-1 and FREESIA-3 Trials of Nipocalimab in Fetal and Neonatal Alloimmune Thrombocytopenia.
Pamela Baker, Babajide Keshinro, Barbara Stegmann...
Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.